On September 18, 2008 at the Koshland Science Museum in Washington, D.C., Dr. Stuart Levy, professor of Molecular Biology and Microbiology at Tufts University School of Medicine and Dr. Linda Tollefson, Assistant Commissioner for Science at the U.S. Food and Drug Administration, discussed how to optimize antibiotic use and how to minimize the emergence of drug resistant pathogens.
In part 2 of this 3 part video series, Dr. Levy discusses how antibiotic resistance develops, the development practices drug companies employ when producing antimicrobials, and how this process may change in the future. Dr. Tollefson outlines how the FDA is encouraging the development of antibiotics in an industry that is mostly focussed on manufacturing drugs for chronic illnesses.
Dr. Levy is Professor of Molecular Biology and Microbiology at Tufts University School of Medicine where he is the Director of the Center for Adaptation Genetics and Drug Resistance. He directs research on mechanisms of bacterial antibiotic ...
